Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
St Pharm Co FCF Yield % Related Terms
St Pharm Co FCF Yield % Historical Data
* Premium members only.
The historical data trend for St Pharm Co's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, St Pharm Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
St Pharm Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, St Pharm Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where St Pharm Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
St Pharm Co (XKRX:237690) has a FCF Yield % of 3.99 as of Sep. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on St Pharm Co and its competitors. According to the industry distribution chart, St Pharm Co ranks #325 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is St Pharm Co's FCF Yield % too high?
St Pharm Co's current FCF Yield % is 3.99. The Drug Manufacturers industry median FCF Yield % is 0.90. St Pharm Co's value of 3.99 is 343.3% above this industry median. Based on the distribution chart, St Pharm Co ranks #325 out of 1004 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, St Pharm Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does St Pharm Co's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, St Pharm Co ranks #325 out of 1004 companies for FCF Yield %. This puts St Pharm Co in the upper half of its industry. The industry median FCF Yield % is 0.90. St Pharm Co's value of 3.99 is 343.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.90, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. St Pharm Co's current FCF Yield % of 3.99 is 343.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on St Pharm Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. St Pharm Co's current FCF Yield % is 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is St Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, St Pharm Co (XKRX:237690) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩116,694.56, compared to a current price of ₩92,700.00 — trading 20.6% below its estimated fair value. The current FCF Yield % is 3.99 and 343.3% above the Drug Manufacturers industry median of 0.90. St Pharm Co's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For St Pharm Co (XKRX:237690), the current FCF Yield % is 3.99 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is St Pharm Co (XKRX:237690) Overvalued in 2026?
Based on GuruFocus' analysis, St Pharm Co stock appears to be undervalued.
The current stock price of ₩92,700.00 is trading 20.6% below its estimated GF Value™ of ₩116,694.56.
GuruFocus considers St Pharm Co to be Modestly Undervalued.
Key valuation signals for XKRX:237690:
FCF Yield %: 3.99
GF Value™: ₩116,694.56 vs. price of ₩92,700.00 (20.6% below fair value)
Industry Position: 343.3% above the Drug Manufacturers median (#325 of 1004)
No single metric tells the full story. See the XKRX:237690 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm's business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical's business and development of oligonucleotide therapeutics. The company's products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
95GF Score
Get the complete analysis for XKRX:237690
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:237690 has been successfully added to your 
